Medscape Journal Club: Alzheimer’s blood biomarkers
- 1 day ago
- 1 min read
Blood biomarkers are rapidly reshaping the diagnosis of Alzheimer's disease -- are they clinic-ready?
Blood biomarkers are rapidly reshaping how we diagnose Alzheimer’s disease, with plasma p-tau217 emerging as one of the most promising biomarkers for earlier, less invasive detection.
But how well does p-tau217 really perform in real-world primary and secondary care? What do the new Alzheimer’s Association clinical practice guidelines say about blood biomarkers being ready for triage or confirmation? And where might key challenges limit routine adoption?
Watch this Journal Club session led by Drs. Cohen, DeMarco, and Laforce as they discuss multi-centre validation data, the 2025 Alzheimer’s Association guidelines, and alternative frameworks.
Through expert discussion and practical prompts, this session explores how close blood biomarkers like p-tau217 are to being truly “clinic-ready” and what clinicians need to consider before integrating them into their practice.
